All In MedTech

Device Trial Radar · NCT07911488

The Encora X1™ in a Real World Observational Study

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

1,000

Planned (sponsor's estimate)

Start

Nov 1, 2026

Primary completion

Nov 2031

Study completion Aug 2032

Sponsor

Lead sponsor
Encora, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Nov 2, 2026

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This research is a post-market study designed to evaluate the long-term, real-world impact of the Encora X1™ on your daily life. The Encora X1™ is a FDA-cleared, wrist-worn, non-invasive neurostimulator device that delivers personalized mechanical stimulation to aid in the relief of hand tremors in adults with essential tremor. A non-invasive device is a device that stays outside of the body. It is not implanted and does not penetrate the skin. Neurostimulation means that the device uses targeted electrical or magnetic pulses to stimulate activity in the nervous system. This study aims to understand how it improves your ability to perform daily activities and your overall satisfaction with the device over a 36-month period. Your feedback will help researchers understand how the device is used over a long period of time in a home environment and improve the delivery of care for individuals with Essential Tremor.

Conditions

  • Essential Tremor

Interventions

  • Encora X1Device

    Encora X1 is indicated to aid in the relief of hand tremors in the treated limb during stimulation in adults with essential tremor.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in the Bain & Findley Activities of Daily Living (BF-ADL) composite score at each scheduled assessment.Time frame: Baseline to Week 1, Months 1, 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36 and Post Treatment Weeks 1, 4 and 8
  2. Change from baseline in the TETRAS PRO composite score at each scheduled assessment.Time frame: Baseline to Week 1, Months 1, 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, and 36
  3. Change from baseline in the QUEST PRO weighted index score at each scheduled assessment.Time frame: Baseline to Week 1, Months 1, 2, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, and 36

11 more outcomes with a free account

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Encora Therapeutics

    Boston, Massachusetts · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.